– December 1, 2004
December 1, 2004
View Issues
-
Insurance Status Predicts Surgical Outcomes for Patients with Colorectal Cancer
Patients without insurance have been reported to have less satisfactory health outcomes, and this has been attributed to a number of factors including access to health care and a greater burden of comorbid conditions. In the current retrospective analysis, short-term outcomes including surgical complications and in-hospital mortality were greater for uninsured or Medicaid recipient colorectal cancer patients (aged, 40-64 years) compared with those with private insurance. -
Risk Factors for Brain Relapse in Patients with Metastatic Breast Cancer
The presence of lung metastases as the first site of relapse and a negative hormone receptor status are predictive for the occurrence of brain metastases in patients with metastatic breast cancer. A prophylactic treatment should be evaluated in these subsets of patients. -
MOHS vs Standard Surgical Excision for Facial Basal Cell Carcinoma
In a randomized, clinical trial, patients with primary or recurrent basal-cell carcinoma were treated either by traditional surgical excision or Mohs micrographic surgery. At 30 months of follow-up, recurrence rates were low in both groups. For those with recurrent disease, there was a suggestion that the Mohs technique might be superior with regard to later recurrence. -
Ductal Lavage: Sensitivity and Specificity in Women with Proven Breast Cancer
The technique of ductal lavage was examined in women who immediately thereafter underwent mastectomy for breast cancer. A physiologic solution was injected into cannulated breast ducts and then aspirated and examined for atypical or frankly malignant cells. -
Timing Isn’t Everything, Right?
Nearly 70% of patients achieving a CR after primary therapy eventually recurred. Most recurrences occurred more than 6 months from completion of primary chemotherapy, and the use of second line agents at the time of recurrence was effective. -
Pharmacology Watch: ACE Inhibitors and Receptor Blockers: Which is Inferior?
The Infection Risk of Acid-Suppressing Drugs; Is Rosuvastatin As Safe As Other Statins?; Which Estrogen Preparation is the Safest?; FDA Actions. -
Clinical Briefs in Primary Care supplement